Overview

The Effect of Intravitreal Ranibizumab on Visual Acuity and Hard Exudate Resolution in the Treatment of Diabetic Macular Edema With Center Involved Edema and Lipid Exudates

Status:
Completed

Trial end date:
2018-05-01

Target enrollment:

Participant gender:

Summary

This is an open-label, Phase I/II study of intravitreally administered 0.3mg ranibizumab in subjects with diabetic macular edema and lipid exudates in the central subfield.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

South Coast Retina Center; Carson, McBeath, Boswell, Inc.

Collaborators:

Doheny Image Reading Center
Genentech, Inc.
Retina Partners

Treatments:

Ranibizumab